INS and Insulin resistance: However, in the recent RCT of Hoseini et al., t-Res demonstrated efficacy in patients affected by type-2 diabetes mellitus and coronary heart disease (CHD) in promoting glycaemic control (reduction of fasting glucose (−10.04 mg/dL; 95%CI, −18.23, −1.86; p= 0.01), insulin (p = 0.01) and insulin resistance (p = 0.001) and improvement of insulin sensitivity (p = 0.02) compared to placebo), HDL-C levels (3.38 mg/dL; 95%CI, 1.72, 5.05; p < 0.001) and total/HDL-C ratio (−0.36; 95% CI, −0.59, −0.13; p = 0.002) as well.